Vimarsana
Biggest News Aggregation in the World

Once Daily News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Once Daily. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Once Daily Today - Breaking & Trending Today

Once Daily Versus Divided Dosing Regimens of Clozapine - Vimarsana News

Once Daily Versus Divided Dosing Regimens of Clozapine

To divide or not to divide? Researchers compared clinical features, side effects, and blood levels between once daily versus divided clozapine dosing regimens.

Best Multivitamins for Men of 2023, Tested by Experts - Vimarsana News

Best Multivitamins for Men of 2023, Tested by Experts

These editor-tested multivitamins for men are third-party tested and contain methylfolate, not folic acid. These are the best multivitamins for men.

Can We Do More for Topical Therapy in Pediatric Atopic Dermatitis? - Vimarsana News

Can We Do More for Topical Therapy in Pediatric Atopic Dermatitis?

It's key for clinicians to optimize therapy prior to systemic agents.

Seasonality returns to the immune support category - Vimarsana News

Seasonality returns to the immune support category

Heightened awareness during the pandemic may have boosted year-round interest in supplementing healthy lifestyles holistically, but retail data shows that consumers have reverted to pre-pandemic habits of priming their immune systems during the cold and flu season.

Enanta Pharmaceuticals, Inc.: Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research - Vimarsana News

Enanta Pharmaceuticals, Inc.: Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that data for EDP-235, its lead 3CL